What is the current overview of cancer immunotherapy in Japan?

Current Overview of Cancer Immunotherapy in Japan

Japan’s cancer immunotherapy landscape is one of the most advanced and regulated in the world, driven by a unique combination of government-backed research initiatives, a rapidly aging population, and a regulatory framework that has accelerated the approval of novel treatments. As of 2025, the Japanese market for cancer immunotherapy is valued at over $8 billion, with a compound annual growth rate (CAGR) of approximately 12% since 2020. This growth is fueled by the widespread adoption of immune checkpoint inhibitors (ICIs), the expansion of chimeric antigen receptor (CAR) T-cell therapies, and the emergence of next-generation modalities like bispecific antibodies and cancer vaccines. The country’s universal healthcare system, managed by the Ministry of Health, Labour and Welfare (MHLW), covers many of these therapies, but access varies by drug and indication, creating a complex but dynamic environment for patients and providers.

The cornerstone of immunotherapy in Japan remains immune checkpoint inhibitors, particularly PD-1 and PD-L1 blockers. Nivolumab (Opdivo), developed by Ono Pharmaceutical in collaboration with Bristol-Myers Squibb, was the first ICI approved in Japan in 2014 for melanoma, and it has since gained approvals for over a dozen indications, including non-small cell lung cancer (NSCLC), renal cell carcinoma, gastric cancer, and head and neck cancers. As of 2024, nivolumab accounted for roughly 30% of all immunotherapy prescriptions in Japan, with annual sales exceeding $2.5 billion. Pembrolizumab (Keytruda), from Merck Sharp & Dohme, is also widely used, approved for indications like NSCLC, urothelial carcinoma, and microsatellite instability-high (MSI-H) solid tumors. Japan’s National Health Insurance (NHI) price listing for pembrolizumab is around ¥1.2 million per 100 mg vial, but patient out-of-pocket costs are capped at 30% under the public insurance system, with further reductions for low-income households. The combination of ICIs with chemotherapy or targeted therapies has become standard practice in Japan, particularly for advanced NSCLC, where the objective response rate (ORR) in clinical trials has reached 45-50% compared to 25-30% with chemotherapy alone.

CAR T-cell therapy has seen significant traction in Japan, driven by the approval of tisagenlecleucel (Kymriah) in 2019 for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Novartis, in partnership with the Japanese biotech firm Takara Bio, operates a centralized manufacturing facility in Tokyo, which processes patient-derived T cells for infusion. As of 2024, over 1,500 patients have received CAR T-cell therapy in Japan, with complete remission rates of 60-70% in pediatric ALL and 50-60% in adult DLBCL. The cost of a single infusion is approximately ¥50 million (about $330,000), but the MHLW has implemented a “value-based pricing” model that ties reimbursement to clinical outcomes, with hospitals receiving additional payments if patients achieve sustained remission at 12 months. This has spurred the development of next-generation CAR T products, including those targeting CD19 and BCMA, with several Japanese startups like Japan Medical overview of cancer immunotherapy in Japan advancing autologous and allogeneic platforms. The regulatory pathway for CAR T cells in Japan is overseen by the Pharmaceuticals and Medical Devices Agency (PMDA), which has adopted a fast-track designation for breakthrough therapies, reducing review times from an average of 12 months to 6 months for priority products.

Bispecific antibodies represent a rapidly growing segment of Japan’s immunotherapy arsenal. Blinatumomab (Blincyto), a CD19-directed CD3 bispecific T-cell engager, was approved in 2018 for relapsed/refractory ALL and has shown an ORR of 43% in Japanese patients in a phase II trial. More recently, teclistamab (Tecvayli), a BCMA-targeting bispecific for multiple myeloma, received PMDA approval in 2023, with a 63% overall response rate in a global trial that included Japanese cohorts. The Japanese market for bispecific antibodies is projected to reach $1.5 billion by 2026, driven by the aging population’s high incidence of hematologic malignancies. Unlike CAR T cells, bispecifics are off-the-shelf products that do not require patient-specific manufacturing, making them more accessible in rural areas where cellular therapy infrastructure is limited. However, cytokine release syndrome (CRS) remains a significant adverse event, occurring in 30-40% of patients, and the MHLW has mandated risk management plans that include hospital-based monitoring for at least 24 hours after the first infusion.

Cancer vaccines, while less dominant than ICIs and cell therapies, are gaining ground in Japan, particularly for prevention and adjuvant settings. The human papillomavirus (HPV) vaccine, which prevents cervical cancer, has been part of Japan’s national immunization program since 2013, but uptake plummeted after a series of unsubstantiated adverse event reports in the media, dropping from 70% to less than 1% by 2016. The MHLW has since reinstated active recommendations in 2022, and coverage has rebounded to 30% as of 2024, with a target of 80% by 2030. For therapeutic vaccines, sipuleucel-T (Provenge), approved for metastatic castration-resistant prostate cancer, has seen limited use in Japan due to its high cost (¥15 million per course) and modest survival benefit of 4.1 months. However, Japanese researchers are pioneering peptide-based vaccines targeting Wilms’ tumor 1 (WT1) and NY-ESO-1 antigens, with phase II trials showing disease stabilization rates of 50-60% in advanced ovarian cancer and sarcoma. The PMDA’s “conditional early approval” system, introduced in 2014, has allowed these vaccines to enter the market based on surrogate endpoints like immune response, with post-marketing surveillance required for full approval.

Regulatory and reimbursement frameworks in Japan are distinct from those in the US or Europe, shaping the immunotherapy landscape in unique ways. The PMDA’s “Sakigake” designation, launched in 2014, grants priority review and consultation for innovative therapies targeting unmet medical needs, with 15 immunotherapy products receiving this status as of 2024. Reimbursement is determined by the Central Social Insurance Medical Council (Chuikyo), which negotiates prices based on cost-effectiveness analyses using the “willingness-to-pay” threshold of ¥5 million per quality-adjusted life year (QALY). This has led to price reductions for some ICIs; for example, the NHI price for nivolumab was cut by 20% in 2023 after a reassessment of its cost-effectiveness in NSCLC. Patient access is further facilitated by the “Advanced Medical Care” system, which allows hospitals to charge extra for unapproved therapies under clinical trial protocols, covering about 10% of immunotherapy patients in Japan. Out-of-pocket costs for standard therapies are capped at ¥100,000 per month for high-cost medical care, but this cap does not apply to CAR T-cell infusions, which are covered under a separate catastrophic illness program.

Clinical trial activity in Japan is robust, with over 200 active immunotherapy trials as of 2025, according to the Japan Registry of Clinical Trials (jRCT). The focus is shifting toward combination strategies, such as ICIs with radiotherapy or oncolytic viruses, and biomarker-driven approaches to identify responders. For instance, the phase III CheckMate 9LA trial, which included Japanese sites, showed that nivolumab plus ipilimumab with two cycles of chemotherapy improved overall survival in NSCLC by 5.6 months compared to chemotherapy alone, leading to PMDA approval in 2022. Japanese patients are also well-represented in global trials for novel agents like the PD-1/VEGF bispecific antibody cadonilimab, which has shown a 45% ORR in gastric cancer in a phase II study. The government’s “Project for Cancer Research and Therapeutic Evolution” (P-CREATE), funded by the Japan Agency for Medical Research and Development (AMED), has allocated ¥30 billion since 2018 to support academic and industry collaborations, with a focus on immunotherapy biomarkers and resistance mechanisms.

Challenges persist, particularly around manufacturing capacity, cost, and equity. Japan’s cell therapy manufacturing sector is concentrated in the Tokyo-Osaka corridor, with only 12 Good Manufacturing Practice (GMP)-certified facilities nationwide, leading to wait times of 4-6 weeks for CAR T-cell production. The MHLW has launched a ¥5 billion subsidy program to build regional manufacturing hubs in Kyushu and Hokkaido, aiming to reduce wait times to 2 weeks by 2027. Cost remains a barrier for some patients, especially for off-label use of ICIs, which are not reimbursed by NHI. A 2024 survey by the Japanese Society of Medical Oncology found that 15% of patients with advanced cancer had considered discontinuing immunotherapy due to financial burden, despite the high-cost medical care cap. Equity issues are also evident in rural areas, where access to CAR T-cell therapy is limited to 20 designated centers, forcing patients to travel hundreds of kilometers for treatment. The government has responded by expanding telemedicine consultations for immunotherapy management and subsidizing travel costs for low-income patients.

Academic research in Japan is pushing the boundaries of immunotherapy, with notable contributions from institutions like the National Cancer Center Japan, Kyoto University, and the University of Tokyo. Kyoto University’s Center for iPS Cell Research and Application (CiRA) is developing induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells for off-the-shelf cancer immunotherapy, with a phase I trial in ovarian cancer showing a 30% response rate without significant CRS. The University of Tokyo’s Institute of Medical Science is pioneering personalized neoantigen vaccines using whole-exome sequencing, with a phase II trial in pancreatic cancer reporting a median survival of 18.5 months compared to 12 months for standard chemotherapy. These academic efforts are supported by AMED’s “Cancer Immunotherapy Acceleration Program,” which has funded 50 projects since 2020, with a total budget of ¥15 billion. The integration of artificial intelligence (AI) for biomarker discovery is also gaining momentum, with a 2024 study from RIKEN using machine learning to predict ICI response in gastric cancer with 85% accuracy based on tumor mutational burden and immune cell infiltration patterns.

The competitive landscape among pharmaceutical companies in Japan is intense, with domestic players like Ono Pharmaceutical, Daiichi Sankyo, and Chugai Pharmaceutical (a Roche subsidiary) leading the charge. Ono’s nivolumab faces competition from Merck’s pembrolizumab and AstraZeneca’s durvalumab, but the company has expanded its pipeline to include next-generation ICIs like the LAG-3 inhibitor ONO-4482, which is in phase II trials for melanoma. Daiichi Sankyo’s antibody-drug conjugate (ADC) platform, particularly trastuzumab deruxtecan (Enhertu), which combines HER2 targeting with a topoisomerase I inhibitor payload, has shown an ORR of 60% in HER2-positive gastric cancer and is now being tested in combination with ICIs. Chugai’s atezolizumab (Tecentriq) is approved for NSCLC and hepatocellular carcinoma, and the company is developing a bispecific antibody targeting PD-1 and CTLA-4, which is in phase I trials. International players like Bristol-Myers Squibb, Merck, and Novartis maintain a strong presence through partnerships and local manufacturing, but the PMDA’s preference for domestic clinical data means that many global trials must include Japanese sites to secure approval, adding 6-12 months to development timelines.

Patient outcomes in Japan are generally favorable compared to global averages, due to early diagnosis and high adherence to treatment protocols. The five-year survival rate for all cancers in Japan is 68%, compared to 67% in the US and 60% in Europe, according to the National Cancer Center Japan. For immunotherapy-responsive cancers like melanoma, the five-year survival rate has improved from 15% in 2010 to 45% in 2024, largely due to ICIs. However, immune-related adverse events (irAEs) are a significant concern, with 30-40% of patients experiencing grade 3 or higher toxicities, including colitis, pneumonitis, and dermatitis. The MHLW has established a national irAE registry, the “Japan Immune-Related Adverse Events Database,” which collects data from 200 hospitals and has published guidelines for managing these events, including the use of corticosteroids and tumor necrosis factor-alpha inhibitors. Despite these measures, a 2023 study found that 5% of immunotherapy patients in Japan required intensive care unit admission for severe irAEs, highlighting the need for better risk stratification.

The future of cancer immunotherapy in Japan looks toward personalized and preventative approaches, with a growing emphasis on liquid biopsies for early detection and monitoring. The “Liquid Biopsy for Cancer Immunotherapy” project, funded by AMED, is developing blood-based assays to detect circulating tumor DNA (ctDNA) and immune cell subsets, with a 2024 pilot study showing that ctDNA clearance after two cycles of ICI therapy predicts 90% of durable responses in NSCLC. The government’s “Cancer Prevention and Control Act,” revised in 2023, includes a goal to increase immunotherapy access for 50% of eligible patients by 2030, with a focus on integrating immunotherapy into standard care pathways for early-stage cancers. The Japan Cancer Society estimates that 1.5 million patients will receive immunotherapy annually by 2030, up from 800,000 in 2024, driven by the approval of new indications and the expansion of manufacturing capacity. However, the sustainability of this growth depends on cost containment, with the MHLW exploring value-based payment models that tie reimbursement to long-term outcomes, similar to the system used for CAR T-cell therapy. The interplay between innovation, regulation, and patient access will continue to define Japan’s role as a global leader in cancer immunotherapy, with the country’s unique demographic and healthcare system providing both opportunities and constraints for the field’s evolution.